Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

RNA Reagent

By R&D Editors | May 10, 2011

Honeywell announced the introduction of a new RNA reagent for use in developing advanced therapeutic medicines.

The product, the Burdick & Jackson rBMI activator, is designed to help laboratories reduce the use of costly amidites, critical ingredients used in the process of making RNA-based medicines, without reducing RNA yield from the process.

The patented formulation is also blended to help the activator remain stable in cold temperatures, which ensures that laboratories will have a product that can be reliably shipped, stored, and handled during the winter months.

The new rBMI activator is formulated to help labs develop therapeutic medicines in a more efficient and productive way. The activator maintains the high level of purity that the pharmaceutical industry has come to expect from Burdick & Jackson for more than five decades.”

Honeywell’s rBMI activator is an extension of the Burdick & Jackson BioSyn line of high-purity DNA and RNA reagents, which are key components in the development of new therapeutic medicines to treat cancer, diabetes, and many other diseases.

The new reagent, consisting of a BMT-type activator, reduces the amount of amidites needed for RNA synthesis without sacrificing the yield of the synthesis, when compared with ETT-type activators. The activator is blended with NMI, a substance that helps to improve the solubility of the formulation. As with all BioSyn reagents, the rBMI activator has low water content for moisture-sensitive applications.

BioSyn DNA and RNA solvents and reagents are engineered to meet the high purity and consistency standards that the pharmaceutical industry requires. A wide range of packaging options, from glass bottles to bulk containers, are available to meet laboratory or production needs.

Honeywell Burdick & Jackson

Related Articles Read More >

Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
2025 R&D layoffs tracker tops 92,000
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE